[five_sixth last=”yes” spacing=”yes” center_content=”no” hide_on_mobile=”no” background_color=”” background_image=”” background_repeat=”no-repeat” background_position=”left top” border_size=”0px” border_color=”” border_style=”” padding=”” margin_top=”” margin_bottom=”” animation_type=”” animation_direction=”” animation_speed=”0.1″ class=”” id=””]

Libraries of new molecules

At PLASMIA we propose as a key objective the obtaining of libraries of new molecules that allow the identification of new compounds with therapeutic action. PLASMIA invests an important proportion of its resources in the R&D of new molecules (New Molecular Entities, NMEs) designed to constitute new active ingredients in medicines of the future.

PLASMIA’s technology, adapted to a miniaturised format, can be used in different phases of the Drug Discovery process, whether in the production of collections of new molecules or in the modification of these molecules to obtain compounds with greater biological activity (Hit to Lead campaign and Lead Optimization).

[/five_sixth]
[five_sixth last=”yes” spacing=”yes” center_content=”no” hide_on_mobile=”no” background_color=”” background_image=”” background_repeat=”no-repeat” background_position=”left top” border_size=”0px” border_color=”” border_style=”” padding=”” margin_top=”” margin_bottom=”” animation_type=”” animation_direction=”” animation_speed=”0.1″ class=”” id=””]

For the development of these libraries of new molecules, PLASMIA has established key partnerships with leading research groups in biocatalysis that allow the design, synthesis and identification of new drugs to be strengthened.

[/five_sixth]